Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Cathepsin B and S as markers for cardiovascular risk and all-cause mortality in patients with stable coronary heart disease during 10 years: a CLARICOR trial sub-study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Apolipoprotein M in patients with chronic kidney disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Effect of simvastatin and ezetimibe on suPAR levels and outcomes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Associations between vitamin D status and atherosclerosis among Inuit in Greenland

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Acupuncture for chronic hepatitis B (Protokol)

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Interventions for altering blood pressure in people with acute subarachnoid haemorrhage (Protocol)

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Radix Sophorae flavescentis for chronic hepatitis B (Protocol)

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

BACKGROUND AND AIMS: The lysosomal cysteine proteases cathepsin B and S have been implicated in the atherosclerotic process. The present paper investigates the association between serum levels of cathepsin B and S and cardiovascular events and mortality in patients with stable coronary heart disease.

METHODS: The CLARICOR trial is a randomised, placebo-controlled trial investigating the effect of clarithromycin versus placebo in patients with stable coronary heart disease. The outcome was time to either a cardiovascular event or all-cause mortality. The placebo group was used as discovery sample and the clarithromycin group as replication sample: n = 1998, n = 1979; mean age (years) 65, 65; 31%, 30% women; follow-up for 10 years; number of composite outcomes n = 1204, n = 1220; respectively. We used a pre-defined multivariable Cox regression model adjusting for inflammation, established cardiovascular risk factors, kidney function, and use of cardiovascular drugs.

RESULTS: Cathepsin B was associated with an increased risk of the composite outcome in both samples after multivariable adjustment (discovery: multivariable ratio (HR) per standard deviation increase 1.12, 95% confidence interval (CI) 1.05-1.19, p < 0.001, replication; HR 1.14, 95% CI 1.07-1.21, p < 0.001). There was no significant association between cathepsin S and the composite outcome in either the discovery or replication sample after multivariable adjustment (p>0.45). Secondary analyses suggest that cathepsin B was predominantly associated with mortality rather than specific cardiovascular events.

CONCLUSIONS: Cathepsin B, but not serum cathepsin S, was associated with an increased risk of cardiovascular events in patients with stable coronary heart disease. The clinical implications of our findings remain to be established.

OriginalsprogEngelsk
TidsskriftAtherosclerosis
Vol/bind278
Sider (fra-til)97-102
Antal sider6
ISSN0021-9150
DOI
StatusUdgivet - 1 nov. 2018

ID: 55375594